Olmesartan Medoxomilo + Hidroclorotiazida Pentafarma (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: provides additional diuretic effect to improve blood pressure control.
• Resistant hypertension: used as part of a multi‑drug regimen when blood pressure remains uncontrolled.
• Hypertension in patients with metabolic syndrome: helps achieve target pressures while minimizing impact on glucose metabolism.
• Hypertension in elderly patients: offers effective blood pressure reduction with a once‑daily dosing schedule.
• Hypertension in patients with chronic kidney disease: assists in blood pressure control while addressing volume overload.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions lower systemic vascular resistance and extracellular fluid volume, resulting in decreased blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.
• Mild gastrointestinal discomfort: occasional nausea or abdominal pain.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring urgent care.
• Severe electrolyte disturbances: significant hyper‑ or hypokalemia.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: elevated liver enzymes.
• Severe hypotension: marked drop in blood pressure leading to syncope.
• Allergic rash or Stevens‑Johnson syndrome: extensive skin reactions.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check serum potassium and sodium before and during treatment.
• Pregnancy: avoid use; teratogenic risk associated with ARBs.
• Concomitant drugs: review for potential additive potassium‑sparing effects.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil + hydrochlorothiazide may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: risk of hyperkalaemia.
• Aliskiren (in diabetic patients): increased renal adverse events.
• NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Lithium: increased lithium levels, risk of toxicity.
• Antidiabetic agents: enhanced hypoglycaemic effect.
• Other antihypertensives: additive blood pressure lowering.
• Corticosteroids: may counteract diuretic effect and alter electrolytes.
• ACE inhibitors: combined use can increase risk of renal impairment and hyperkalaemia.